• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 6-K/A filed by Sol-Gel Technologies Ltd.

    5/8/25 9:38:47 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLGL alert in real time by email
    6-K/A 1 zk2533144.htm 6-K


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 6-K/A
     
    Report of Foreign Private Issuer
    Pursuant to Rule 13a-16 or 15d-16
    Under the Securities Exchange Act of 1934
     
    For the month of August 2024
     
    Commission File Number 001-38367
     
    SOL-GEL TECHNOLOGIES LTD.
    (Translation of registrant’s name into English)
     
    7 Golda Meir Street
    Ness Ziona 7403650, Israel
    (Address of principal executive offices)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
     
    Form 20-F ☒           Form 40-F ☐
     
    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
     
    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐



    Explanatory Note
     
    Sol-Gel Technologies Ltd. (the “Company”) is amending its Report on Form 6-K furnished to the U.S. Securities and Exchange Commission (the “Commission”) on May 5, 2025 (the “Original Form 6-K”) solely to revise the incorporation by reference language included in the last paragraph of the Form 6-K to include reference to the Company’s Registration Statement on Form S-8 (Registration No. 333-286820) filed on April 29, 2025 and the Company’s Registration Statement on F-3 (Registration No  333-286822) filed on April 29, 2025. Other than as set forth below, the information contained in the Original Form 6-K remains unchanged.

    The incorporation by reference paragraph in the Original Form 6-K is hereby amended and restated as follows:

    “This Report is incorporated by reference into the Company’s registration statements on Form S-8 (Registration Nos. 333-223915,  333-270477 and  333-286820), and Form F-3 (Registration No  333-286822), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.”
     
    2


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
     
    SOL-GEL TECHNOLOGIES LTD.
       
     
    Date:  May 8, 2025
    By:
    /s/ Eyal Ben-Or
     
     
    Eyal Ben-Or
     
     
    Chief Financial Officer

    3

    Get the next $SLGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLGL

    DatePrice TargetRatingAnalyst
    8/19/2024$6.00 → $4.00Strong Buy → Outperform
    Raymond James
    10/21/2022$5.50Hold
    Jefferies
    11/15/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    11/12/2021$23.00 → $21.00Strong Buy
    Raymond James
    7/28/2021$20.00 → $21.00Buy
    HC Wainwright & Co.
    7/12/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SLGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sol-Gel downgraded by Raymond James with a new price target

      Raymond James downgraded Sol-Gel from Strong Buy to Outperform and set a new price target of $4.00 from $6.00 previously

      8/19/24 6:57:49 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Sol-Gel with a new price target

      Jefferies resumed coverage of Sol-Gel with a rating of Hold and set a new price target of $5.50

      10/21/22 7:42:15 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sol-Gel Technologies with a new price target

      HC Wainwright & Co. reiterated coverage of Sol-Gel Technologies with a rating of Buy and set a new price target of $20.00 from $21.00 previously

      11/15/21 1:18:47 PM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Sol-Gel Technologies Ltd.

      SCHEDULE 13D/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

      6/12/25 4:40:41 PM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Sol-Gel Technologies Ltd.

      424B3 - Sol-Gel Technologies Ltd. (0001684693) (Filer)

      5/23/25 7:17:09 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Sol-Gel Technologies Ltd.

      6-K - Sol-Gel Technologies Ltd. (0001684693) (Filer)

      5/23/25 7:15:16 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    Financials

    Live finance-specific insights

    See more
    • Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

      An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib gel, 2%), an Orphan Drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome and partnered with Galderma to commercialize two approved lar

      3/13/24 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Phase 1 trial for SGT-210 (erlotinib) demonstrated no systemic absorption-related adverse events; Sol-Gel intends to advance this drug candidate Sol-Gel has cash runway into the second half of 2025 NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched in the U.S., SGT-610, which is Phase 3

      5/12/23 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

      Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndromeA Phase 3 study of SGT-610 is expected to initiate in the second half of 2023, with results expected by the end of 2025The base of recurrent TWYNEO® prescribers was 82% in Q4 2022, while the EPSOLAY® recurrent prescriber base has grown to 64% during the same periodFollowing recent financing, Sol-Gel's cash runway expected to extend into the second half of 2025 NESS ZIONA, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company wi

      3/10/23 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care